

Supporting Information, SI_A1_Table_S2a

Summary of regimens applied to classic EPF (including a case of EEDF)

Classic EPF	Common Tx	Delivery	CR	PR	D	NR	U	Σ	Σ-U	CR (%)	Efficacy (%)	Share (%)	adj%CR	adj%E	Acuity (%)	adj%Acuity	
	Steroids/topical	Topical	9	51	0	89	16	165	149	6.0	40.3	18.8	1.1	7.6	15.0	2.8	
	Steroids/systemic	Systemic	22	54	0	25	4	105	101	21.8	75.2	12.0	2.6	9.0	28.9	3.5	
	↓ Tacrolimus	Topical	11	7	0	5	0	23	23	47.8	78.3	2.6	1.3	2.1	61.1	1.6	
	↓ Pimecrolimus	Topical	1	0	0	1	0	2	2	50.0	50.0	0.2	0.1	0.1	100.0	0.2	
	Tacrolimus[†]	Topical	12	7	0	6	0	25	25	48.0	76.0	2.8	1.4	2.2	63.2	1.8	
	DDS	Systemic	15	34	0	33	2	84	82	18.3	59.8	9.6	1.8	5.7	30.6	2.9	
	Sulfonamides	Systemic	2	5	0	8	0	15	15	13.3	46.7	1.7	0.2	0.8	28.6	0.5	
	↓ Minocycline	Systemic	9	22	0	38	5	74	69	13.0	44.9	8.4	1.1	3.8	29.0	2.4	
	↓ Other tetracyclines	Systemic	3	2	0	13	0	18	18	16.7	27.8	2.1	0.3	0.6	60.0	1.2	
	Tetracyclines[‡]	Systemic	12	24	0	51	5	92	87	13.8	41.4	10.5	1.4	4.3	33.3	3.5	
	Macrolides[§]	Systemic	2	2	0	11	7	22	15	13.3	26.7	2.5	0.3	0.7	50.0	1.3	
	↓ Other antibiotics	Systemic	1	2	0	18	2	23	21	4.8	14.3	2.6	0.1	0.4	33.3	0.9	
	↓ Other antibiotics	Topical	0	0	0	2	0	2	2	0.0	0.0	0.2	0.0	0.0	N/A	N/A	
	Other antibiotics	N/A	1	2	0	20	2	25	23	4.3	13.0	2.8	0.1	0.4	33.3	0.9	
	↓ Metronidazole	Systemic	1	0	0	0	0	1	1	100.0	100.0	0.1	0.1	0.1	100.0	0.1	
	↓ Permethrin	Topical	0	0	0	0	0	0	0	N/A	N/A	0.0	N/A	N/A	N/A	N/A	
	↓ Ketoconazole	Topical	0	0	0	0	0	0	0	N/A	N/A	0.0	N/A	N/A	N/A	N/A	
	↓ Other antifungals	Systemic	0	0	0	3	0	3	3	0.0	0.0	0.3	0.0	0.0	N/A	N/A	
	↓ Other antifungals	Topical	0	0	0	3	0	3	3	0.0	0.0	0.3	0.0	0.0	N/A	N/A	
	Antifungals[¶]	N/A	1	0	0	6	0	7	7	14.3	14.3	0.8	0.1	0.1	100.0	0.8	
	↓ Indomethacin	Topical	7	18	1	7	5	38	33	21.2	75.8	4.3	0.9	3.3	28.0	1.2	
	↓ Indomethacin	Systemic	74	63	1	19	5	162	157	47.1	87.3	18.5	8.7	16.1	54.0	10.0	
	↓ Indomethacin farnesyl	Systemic	2	1	0	5	0	8	8	25.0	37.5	0.9	0.2	0.3	66.7	0.6	
	↓ Acemetacin	Systemic	2	5	0	0	0	7	7	28.6	100.0	0.8	0.2	0.8	28.6	0.2	
	↓ Proglumetacin	Systemic	0	0	0	1	0	1	1	0.0	0.0	0.1	0.0	0.0	N/A	N/A	
	Indomethacins[††]	N/A	85	87	2	32	10	216	206	41.3	83.5	24.6	10.2	20.5	49.4	12.2	
	↓ Loxoprofen	Systemic	0	2	0	0	0	5	5	0.0	40.0	0.6	0.0	0.2	0.0	0.0	
	↓ Naproxen	Systemic	4	3	0	3	1	11	10	40.0	70.0	1.3	0.5	0.9	57.1	0.7	
	↓ Other NSAIDs	Systemic	2	5	1	6	1	15	14	14.3	50.0	1.7	0.2	0.9	28.6	0.5	
	↓ Other NSAIDs	Topical	1	2	0	5	3	11	8	12.5	37.5	1.3	0.2	0.5	33.3	0.4	
	Other NSAIDs[‡‡]	N/A	7	12	1	17	5	42	37	18.9	51.4	4.8	0.9	2.5	36.8	1.8	
	Cyclosporine	Systemic	5	6	0	5	0	16	16	31.3	68.8	1.8	0.6	1.3	45.5	0.8	
	↓ UV (unspecified ba)	N/A	0	0	0	0	0	0	0	N/A	N/A	0.0	N/A	N/A	N/A	N/A	
	↓ UVA	N/A	3	0	0	3	0	6	6	50.0	50.0	0.7	0.3	0.3	100.0	0.7	
	↓ UVB	N/A	1	2	0	0	3	3	33.3	100.0	0.3	0.1	0.3	33.3	0.1		
	↓ NB-UVB	N/A	1	1	0	1	0	3	3	33.3	66.7	0.3	0.1	0.2	50.0	0.2	
	Ultraviolet	N/A	5	3	0	4	0	12	12	41.7	66.7	1.4	0.6	0.9	62.5	0.9	
	Retinoids[§§]	Systemic	4	1	0	4	0	9	9	44.4	55.6	1.0	0.5	0.6	80.0	0.8	
	Nicotine	Cutaneous	5	1	0	2	0	8	8	62.5	75.0	0.9	0.6	0.7	83.3	0.8	
	Subtotal	N/A	187	289	3	313	51	843	792	N/A	N/A	96.0	N/A	N/A	N/A	N/A	
	Classic EPF	Uncommon Tx	Delivery	CR	PR	D	NR	U	Σ	Σ-U	CR (%)	Efficacy (%)	Share (%)	adj%CR	adj%E	Acuity (%)	adj%Acuity
	Sairei-To (a Chinese)	Systemic	3	4	0	0	0	7	7	42.9	100.0	0.8	0.3	0.8	42.9	0.3	
	IFN-γ	Systemic	3	1	0	0	0	4	4	75.0	100.0	0.46	0.3	0.5	75.0	0.3	
	IFN-α	Systemic	1	0	0	1	0	2	2	50.0	50.0	0.23	0.1	0.1	100.0	0.2	
	Eicosapentaenoic acid	Systemic	1	0	0	1	0	2	2	50.0	50.0	0.23	0.1	0.1	100.0	0.2	
	Colchicine	Systemic	0	0	0	2	0	2	2	0.0	0.0	0.23	0.0	0.0	N/A	N/A	
	Suplatast tosilate	Systemic	1	0	0	0	1	1	1	100.0	100.0	0.11	0.1	0.1	100.0	0.1	
	Trilast	Systemic	1	0	0	0	1	1	1	100.0	100.0	0.11	0.1	0.1	100.0	0.1	
	Tramincione	Topical inj	1	0	0	0	1	1	1	100.0	100.0	0.11	0.1	0.1	100.0	0.1	
	Infliximab (anti-TNF)	Systemic	0	1	0	0	0	1	1	0.0	100.0	0.11	0.0	0.1	0.0	0.0	
	Alphacalcidol	ND	0	1	0	0	0	1	1	0.0	100.0	0.11	0.0	0.1	0.0	0.0	
	Nicotinamide	Systemic	0	1	0	0	0	1	1	0.0	100.0	0.11	0.0	0.1	0.0	0.0	
	Glyteer (dry distillat)	Topical	0	1	0	0	0	1	1	0.0	100.0	0.11	0.0	0.1	0.0	0.0	
	Hypo-sensitization	ND	0	1	0	0	0	1	1	0.0	100.0	0.11	0.0	0.1	0.0	0.0	
	Nicentrol (a nicotini)	Systemic	0	0	0	1	0	1	1	0.0	0.0	0.11	0.0	0.0	N/A	N/A	
	Biotin	Systemic	0	0	0	1	0	1	1	0.0	0.0	0.11	0.0	0.0	N/A	N/A	
	Tranexamic acid	Systemic	0	0	0	1	0	1	1	0.0	0.0	0.11	0.0	0.0	N/A	N/A	
	Potassium iodide	Systemic	0	0	0	0	1	1	0	N/A	N/A	0.11	N/A	N/A	N/A	N/A	
	Tonsillectomy	N/A	0	0	0	1	0	1	1	0.0	0.0	0.11	0.0	0.0	N/A	N/A	
	Electron beam	N/A	1	0	0	0	0	1	1	100.0	100.0	0.11	0.1	0.1	100.0	0.1	
	Replacement of de	N/A	2	0	0	0	0	2	2	100.0	100.0	0.23	0.2	0.2	100.0	0.2	
	Treatment of denta	N/A	1	0	0	1	0	2	2	50.0	50.0	0.23	0.1	0.1	100.0	0.2	
	Subtotal	N/A	15	10	0	9	1	35	34	N/A	N/A	3.99	N/A	N/A	N/A	N/A	
	Whole	N/A	202	299	3	322	52	878	826	N/A	N/A	100.0	N/A	N/A	N/A	N/A	

赤数字は奏効率%で、完全寛解は青字%です。
 <-これがインドメタシン内服 (インテパンSPふくむ)
 <-インドメタシンファルネシル (インフリー)
 <-アセメタシン

"Common regimens" indicate the regimens, the category of which appeared eight times or more in the whole literature published between 1965 and 2013
 CR, complete response: description of "significance" or "success" of the regimen; description of complete clearance or significant amelioration of the lesion
 PR, partial response: description of "effectiveness" or "usefulness" of the regimen; description of partial clearance or manageability of the lesion
 D, deterioration: description of deterioration of the lesion due to the applied regimen
 NR, no response: description of no beneficial effect of the regimen; no change or unresponsiveness of the lesion
 U, unknown: no description of the outcome
 Σ: number of cases, or the sum case number of CR, PR, D, NR, and U
 CR (%) = CR/(CR+PR+D+NR) x 100
 Efficacy (%) = (CR+PR)/(CR+PR+D+NR) x 100
 Acuity (%) = CR/(CR+PR) x 100
 Share (%) = (Σ of each category)/(Whole Σ or 878) x 100
 adj%CR (%) = CR/Share x 100; adj%E (%) = Efficacy/Share x 100; adjAcuity (%) = Acuity/Share x 100

"|" indicates that the row concerned is added to the bottom of each outlined section
 † Tacrolimus or pimecrolimus
 ‡ Tetracycline, minocycline, or doxycycline
 § Oleandomycin, erythromycin, roxithromycin, clarithromycin, or azithromycin
 ¶ Metronidazole and permethrin are grouped as antifungals
 †† Indomethacin prodrugs, or indomethacin farnesyl and acemetacin, are grouped as "indomethacins"
 ‡‡ Loxoprofen, naproxen, or other NSAIDs
 §§ Etreinate, tretinoin, isotretinoin, or acitretin

Abbreviations: UV, ultraviolet; UVA, ultraviolet A; UVB, ultraviolet B; NB-UVB, narrowband UVB; N/A, not applicable
 This table was made based on the original data, which are uploaded as "SI_EPF_Tx_Pubmed_Ichushi_ver151216.xlsx"
 Note: numbers of PR for steroids/systemic. NR for DDS. NR for indomethacin/systemic, and CR for UVA, are added by 1 each compared to the previously published data, because the result of report by Calzavara-Pinton et al. is added for classic EPF